Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

CompletedOBSERVATIONAL
Enrollment

812

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
DIAGNOSTIC_TEST

Diagnosis of TTR amyloidosis cardiomyopathy

Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy

Trial Locations (18)

1000

University Medical Centre Ljubljana - Department of Cardiology, Ljubljana

4011

East Slovak Institute of Cardiovascular Diseases, Košice

4102

The Prince Charles Hospital, Chermside

14033

Centre Hospitalier Universitaire de Caen, Caen

15006

Hospital Universitario A Coruna, A Coruña

28222

Cardiomyopathy Unit, Department of Cardiology, Majadahonda

31100

CHU de Toulouse, Toulouse

40128

Divisione di Cardiologia, Bologna

44093

CHU de Nantes, Nantes

50134

Careggi Hospital, Florence

94000

Hopital Henri Mondor, Service de Pharmacologie Clinique, Créteil

Unknown

The Alfred Department of Cardiology, Melbourne

A-6020

Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie, Innsbruck

3000-075

Centro Hospitalar e Universitario de Coimbra, Coimbra

1150-199

Centro Hospitalar de Lisboa Central, E.P.E., Lisbon

022328

Fundeni Clinical Institute, Bucharest

030171

Inherited Cardiovascular Diseases - Cardiology Institute, Bucharest

W1G 8PH

The Heart Hospital - University College London Hospitals Nhs Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY